Kastle Therapeutics, LLC Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Chicago IL United States (2015)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

KASTLE THERAPS LLC

Active Ingredients

Marketed Drugs (1)

mipomersen (kynamro) (2013)

Drugs in Phase 3 Trials (1)

mipomersen (kynamro) (18 trials)

Drugs in Phase 1 Trials (2)

moxifloxacin (avelox) (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Congenital Abnormalities (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Disease (Phase 3)

Dyslipidemias (Phase 3)

Genetic Diseases, Inborn (Phase 3)

Heart Diseases (Phase 3)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Hyperlipoproteinemia Type II (Phase 3)

Hypobetalipoproteinemias (Phase 2)

Hypolipoproteinemias (Phase 2)

Infant, Newborn, Diseases (Phase 3)

Lipid Metabolism Disorders (Phase 3)

Lipid Metabolism, Inborn Errors (Phase 3)

Metabolic Diseases (Phase 3)

Metabolism, Inborn Errors (Phase 3)

Myocardial Ischemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 3